ID   PCSK9_HUMAN             Reviewed;         692 AA.
AC   Q8NBP7; A8T640; C0JYY9; Q5PSM5; Q5SZQ2;
DT   07-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 3.
DT   18-JUN-2025, entry version 216.
DE   RecName: Full=Proprotein convertase subtilisin/kexin type 9;
DE            EC=3.4.21.-;
DE   AltName: Full=Neural apoptosis-regulated convertase 1;
DE            Short=NARC-1;
DE   AltName: Full=Proprotein convertase 9;
DE            Short=PC9;
DE   AltName: Full=Subtilisin/kexin-like protease PC9;
DE   Flags: Precursor;
GN   Name=PCSK9; Synonyms=NARC1; ORFNames=PSEC0052;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ILE-474 AND GLU-670.
RA   Chiang L.W.;
RT   "Nucleic acid molecules derived from rat brain and programmed cell death
RT   models.";
RL   Patent number WO0131007, 03-MAY-2001.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ILE-474 AND GLU-670.
RX   PubMed=17971861; DOI=10.1371/journal.pone.0001098;
RA   Ding K., McDonough S.J., Kullo I.J.;
RT   "Evidence for positive selection in the C-terminal domain of the
RT   cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14
RT   primate species.";
RL   PLoS ONE 2:E1098-E1098(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ILE-474.
RC   TISSUE=Cerebellum, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-23 INS; LEU-46; VAL-53;
RP   SER-425; THR-443; ILE-474; ARG-553; PRO-619 AND GLU-670.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-23 INS; ILE-474 AND
RP   GLU-670.
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS ILE-474 AND
RP   GLU-670.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   PROTEIN SEQUENCE OF N-TERMINUS, CHARACTERIZATION, AND MUTAGENESIS OF
RP   CYS-67; HIS-226 AND ASN-533.
RX   PubMed=12552133; DOI=10.1073/pnas.0335507100;
RA   Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B.,
RA   Stifani S., Basak A., Prat A., Chretien M.;
RT   "The secretory proprotein convertase neural apoptosis-regulated convertase
RT   1 (NARC-1): liver regeneration and neuronal differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:928-933(2003).
RN   [9]
RP   AUTOCATALYTIC CLEAVAGE AT GLN-152.
RX   PubMed=14622975; DOI=10.1016/j.abb.2003.09.011;
RA   Naureckiene S., Ma L., Sreekumar K., Purandare U., Lo C.F., Huang Y.,
RA   Chiang L.W., Grenier J.M., Ozenberger B.A., Jacobsen J.S., Kennedy J.D.,
RA   DiStefano P.S., Wood A., Bingham B.;
RT   "Functional characterization of Narc 1, a novel proteinase related to
RT   proteinase K.";
RL   Arch. Biochem. Biophys. 420:55-67(2003).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   GLYCOSYLATION AT ASN-533, SULFATION AT TYR-38, AND PROTEOLYTIC CLEAVAGE AT
RP   ARG-218 BY FURIN AND PCSK5.
RX   PubMed=16912035; DOI=10.1074/jbc.m606495200;
RA   Benjannet S., Rhainds D., Hamelin J., Nassoury N., Seidah N.G.;
RT   "The proprotein convertase (PC) PCSK9 is inactivated by furin and/or
RT   PC5/6A: functional consequences of natural mutations and post-translational
RT   modifications.";
RL   J. Biol. Chem. 281:30561-30572(2006).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH LDLR.
RX   PubMed=17461796; DOI=10.1111/j.1600-0854.2007.00562.x;
RA   Nassoury N., Blasiole D.A., Tebon Oler A., Benjannet S., Hamelin J.,
RA   Poupon V., McPherson P.S., Attie A.D., Prat A., Seidah N.G.;
RT   "The cellular trafficking of the secretory proprotein convertase PCSK9 and
RT   its dependence on the LDLR.";
RL   Traffic 8:718-732(2007).
RN   [13]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=18197702; DOI=10.1021/bi7016359;
RA   Fan D., Yancey P.G., Qiu S., Ding L., Weeber E.J., Linton M.F., Fazio S.;
RT   "Self-association of human PCSK9 correlates with its LDLR-degrading
RT   activity.";
RL   Biochemistry 47:1631-1639(2008).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH BACE1.
RX   PubMed=18660751; DOI=10.1038/embor.2008.132;
RA   Jonas M.C., Costantini C., Puglielli L.;
RT   "PCSK9 is required for the disposal of non-acetylated intermediates of the
RT   nascent membrane protein BACE1.";
RL   EMBO Rep. 9:916-922(2008).
RN   [15]
RP   PHOSPHORYLATION AT SER-47 AND SER-688, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=18498363; DOI=10.1111/j.1742-4658.2008.06495.x;
RA   Dewpura T., Raymond A., Hamelin J., Seidah N.G., Mbikay M., Chretien M.,
RA   Mayne J.;
RT   "PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and
RT   circulates as a phosphoprotein in humans.";
RL   FEBS J. 275:3480-3493(2008).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH VLDLR AND LRP8/APOER2.
RX   PubMed=18039658; DOI=10.1074/jbc.m708098200;
RA   Poirier S., Mayer G., Benjannet S., Bergeron E., Marcinkiewicz J.,
RA   Nassoury N., Mayer H., Nimpf J., Prat A., Seidah N.G.;
RT   "The proprotein convertase PCSK9 induces the degradation of low density
RT   lipoprotein receptor (LDLR) and its closest family members VLDLR and
RT   ApoER2.";
RL   J. Biol. Chem. 283:2363-2372(2008).
RN   [17]
RP   FUNCTION, INTERACTION WITH ANXA2, VARIANT FHCL3 TYR-374, CHARACTERIZATION
RP   OF VARIANT FHCL3 TYR-374, VARIANT GLU-554, AND CHARACTERIZATION OF VARIANT
RP   GLU-554.
RX   PubMed=18799458; DOI=10.1074/jbc.m805971200;
RA   Mayer G., Poirier S., Seidah N.G.;
RT   "Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous
RT   low density lipoprotein receptor levels.";
RL   J. Biol. Chem. 283:31791-31801(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   FUNCTION.
RX   PubMed=22074827; DOI=10.1016/j.bbrc.2011.10.110;
RA   Chen Y., Wang H., Yu L., Yu X., Qian Y.W., Cao G., Wang J.;
RT   "Role of ubiquitination in PCSK9-mediated low-density lipoprotein receptor
RT   degradation.";
RL   Biochem. Biophys. Res. Commun. 415:515-518(2011).
RN   [21]
RP   INTERACTION WITH LDLR.
RX   PubMed=21149300; DOI=10.1074/jbc.m110.199042;
RA   Yamamoto T., Lu C., Ryan R.O.;
RT   "A two-step binding model of PCSK9 interaction with the low density
RT   lipoprotein receptor.";
RL   J. Biol. Chem. 286:5464-5470(2011).
RN   [22]
RP   DOMAIN C-TERMINAL.
RX   PubMed=22027821; DOI=10.1074/jbc.m111.273474;
RA   Du F., Hui Y., Zhang M., Linton M.F., Fazio S., Fan D.;
RT   "Novel domain interaction regulates secretion of proprotein convertase
RT   subtilisin/kexin type 9 (PCSK9) protein.";
RL   J. Biol. Chem. 286:43054-43061(2011).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [24]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH APOB.
RX   PubMed=22580899; DOI=10.1161/atvbaha.112.250043;
RA   Sun H., Samarghandi A., Zhang N., Yao Z., Xiong M., Teng B.B.;
RT   "Proprotein convertase subtilisin/kexin type 9 interacts with
RT   apolipoprotein B and prevents its intracellular degradation, irrespective
RT   of the low-density lipoprotein receptor.";
RL   Arterioscler. Thromb. Vasc. Biol. 32:1585-1595(2012).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   PHOSPHORYLATION AT SER-47 AND SER-688.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [27]
RP   REVIEW.
RX   PubMed=18280815; DOI=10.1016/j.bbalip.2008.01.003;
RA   Lopez D.;
RT   "PCSK9: an enigmatic protease.";
RL   Biochim. Biophys. Acta 1781:184-191(2008).
RN   [28]
RP   REVIEW.
RX   PubMed=18649882; DOI=10.1016/j.atherosclerosis.2008.06.010;
RA   Lambert G., Charlton F., Rye K.A., Piper D.E.;
RT   "Molecular basis of PCSK9 function.";
RL   Atherosclerosis 203:1-7(2009).
RN   [29]
RP   REVIEW.
RX   PubMed=19930098; DOI=10.1111/j.1365-2796.2009.02167.x;
RA   Mousavi S.A., Berge K.E., Leren T.P.;
RT   "The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol
RT   homeostasis.";
RL   J. Intern. Med. 266:507-519(2009).
RN   [30]
RP   REVIEW.
RX   PubMed=19020338; DOI=10.1194/jlr.r800091-jlr200;
RA   Horton J.D., Cohen J.C., Hobbs H.H.;
RT   "PCSK9: a convertase that coordinates LDL catabolism.";
RL   J. Lipid Res. 50:S172-S177(2009).
RN   [31]
RP   REVIEW.
RX   PubMed=21943799; DOI=10.1016/j.numecd.2011.06.002;
RA   Tibolla G., Norata G.D., Artali R., Meneghetti F., Catapano A.L.;
RT   "Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-
RT   function relation to therapeutic inhibition.";
RL   Nutr. Metab. Cardiovasc. Dis. 21:835-843(2011).
RN   [32]
RP   POLYMORPHISM, AND VARIANT SER-174.
RX   PubMed=22417841; DOI=10.1016/j.atherosclerosis.2012.02.018;
RA   Slimani A., Jelassi A., Jguirim I., Najah M., Rebhi L., Omezzine A.,
RA   Maatouk F., Hamda K.B., Kacem M., Rabes J.P., Abifadel M., Boileau C.,
RA   Rouis M., Slimane M.N., Varret M.;
RT   "Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in
RT   Tunisian familial hypercholesterolemia patients.";
RL   Atherosclerosis 222:158-166(2012).
RN   [33]
RP   FUNCTION, AND INTERACTION WITH SCNN1A; SCNN1B AND SCNN1G.
RX   PubMed=22493497; DOI=10.1074/jbc.m112.363382;
RA   Sharotri V., Collier D.M., Olson D.R., Zhou R., Snyder P.M.;
RT   "Regulation of epithelial sodium channel trafficking by proprotein
RT   convertase subtilisin/kexin type 9 (PCSK9).";
RL   J. Biol. Chem. 287:19266-19274(2012).
RN   [34]
RP   FUNCTION, INTERACTION WITH ANXA2, VARIANT GLN-482, CHARACTERIZATION OF
RP   VARIANT GLN-482, VARIANTS FHCL3 SER-218 AND TYR-374, CHARACTERIZATION OF
RP   VARIANTS FHCL3 SER-218 AND TYR-374, SULFATION, PHOSPHORYLATION,
RP   GLYCOSYLATION, AND SUBUNIT.
RX   PubMed=24808179; DOI=10.1074/jbc.m113.541094;
RA   Ly K., Saavedra Y.G., Canuel M., Routhier S., Desjardins R., Hamelin J.,
RA   Mayne J., Lazure C., Seidah N.G., Day R.;
RT   "Annexin A2 reduces PCSK9 protein levels via a translational mechanism and
RT   interacts with the M1 and M2 domains of PCSK9.";
RL   J. Biol. Chem. 289:17732-17746(2014).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 31-692.
RX   PubMed=17502100; DOI=10.1016/j.str.2007.04.004;
RA   Piper D.E., Jackson S., Liu Q., Romanow W.G., Shetterly S., Thibault S.T.,
RA   Shan B., Walker N.P.;
RT   "The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol.";
RL   Structure 15:545-552(2007).
RN   [36]
RP   VARIANTS FHCL3 ARG-127 AND LEU-216, AND VARIANTS LEU-46; VAL-53 AND
RP   GLU-670.
RX   PubMed=12730697; DOI=10.1038/ng1161;
RA   Abifadel M., Varret M., Rabes J.-P., Allard D., Ouguerram K., Devillers M.,
RA   Cruaud C., Benjannet S., Wickham L., Erlich D., Derre A., Villeger L.,
RA   Farnier M., Beucler I., Bruckert E., Chambaz J., Chanu B., Lecerf J.-M.,
RA   Luc G., Moulin P., Weissenbach J., Prat A., Krempf M., Junien C.,
RA   Seidah N.G., Boileau C.;
RT   "Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.";
RL   Nat. Genet. 34:154-156(2003).
RN   [37]
RP   VARIANTS LEU-46; VAL-53; LYS-57; TRP-237; PHE-253; ASN-391; GLN-417;
RP   SER-425; THR-443; TRP-469; ILE-474; GLY-482; LEU-515; ARG-553; GLU-554;
RP   PRO-619 AND GLU-670.
RX   PubMed=16465619; DOI=10.1086/500615;
RA   Kotowski I.K., Pertsemlidis A., Luke A., Cooper R.S., Vega G.L.,
RA   Cohen J.C., Hobbs H.H.;
RT   "A spectrum of PCSK9 alleles contributes to plasma levels of low-density
RT   lipoprotein cholesterol.";
RL   Am. J. Hum. Genet. 78:410-422(2006).
RN   [38]
RP   VARIANTS FHCL3 GLY-129; HIS-215; HIS-357; HIS-374 AND TRP-496.
RX   PubMed=19191301; DOI=10.1002/humu.20882;
RA   Abifadel M., Rabes J.P., Devillers M., Munnich A., Erlich D., Junien C.,
RA   Varret M., Boileau C.;
RT   "Mutations and polymorphisms in the proprotein convertase subtilisin kexin
RT   9 (PCSK9) gene in cholesterol metabolism and disease.";
RL   Hum. Mutat. 30:520-529(2009).
RN   [39]
RP   POLYMORPHISM, VARIANT LEU-23 INS, AND IMPACT ON FAMILIAL
RP   HYPERCHOLESTEROLEMIA.
RX   PubMed=19319977; DOI=10.1002/humu.21002;
RA   Abifadel M., Rabes J.-P., Jambart S., Halaby G., Gannage-Yared M.-H.,
RA   Sarkis A., Beaino G., Varret M., Salem N., Corbani S., Aydenian H.,
RA   Junien C., Munnich A., Boileau C.;
RT   "The molecular basis of familial hypercholesterolemia in Lebanon: spectrum
RT   of LDLR mutations and role of PCSK9 as a modifier gene.";
RL   Hum. Mutat. 30:E682-E691(2009).
RN   [40]
RP   POLYMORPHISM, VARIANT FHCL3 SER-394, AND VARIANTS LEU-23 INS; LEU-46;
RP   VAL-53; ILE-474 AND GLU-670.
RX   PubMed=22095935; DOI=10.1002/humu.21660;
RA   Huijgen R., Sjouke B., Vis K., de Randamie J.S., Defesche J.C.,
RA   Kastelein J.J., Hovingh G.K., Fouchier S.W.;
RT   "Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic
RT   autosomal dominant hypercholesterolemic mutations with unexpected low LDL-
RT   Cl Levels.";
RL   Hum. Mutat. 33:448-455(2012).
CC   -!- FUNCTION: Crucial player in the regulation of plasma cholesterol
CC       homeostasis. Binds to low-density lipid receptor family members: low
CC       density lipoprotein receptor (LDLR), very low density lipoprotein
CC       receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and
CC       apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation
CC       in intracellular acidic compartments (PubMed:18039658). Acts via a non-
CC       proteolytic mechanism to enhance the degradation of the hepatic LDLR
CC       through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the
CC       recycling of LDLR from endosomes to the cell surface or direct it to
CC       lysosomes for degradation. Can induce ubiquitination of LDLR leading to
CC       its subsequent degradation (PubMed:17461796, PubMed:18197702,
CC       PubMed:18799458, PubMed:22074827). Inhibits intracellular degradation
CC       of APOB via the autophagosome/lysosome pathway in a LDLR-independent
CC       manner. Involved in the disposal of non-acetylated intermediates of
CC       BACE1 in the early secretory pathway (PubMed:18660751). Inhibits
CC       epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing
CC       ENaC surface expression primarily by increasing its proteasomal
CC       degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2
CC       levels and related anti-apoptotic signaling pathways.
CC       {ECO:0000269|PubMed:17461796, ECO:0000269|PubMed:18039658,
CC       ECO:0000269|PubMed:18197702, ECO:0000269|PubMed:18660751,
CC       ECO:0000269|PubMed:18799458, ECO:0000269|PubMed:22074827,
CC       ECO:0000269|PubMed:22493497, ECO:0000269|PubMed:22580899}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000305};
CC   -!- ACTIVITY REGULATION: Its proteolytic activity is autoinhibited by the
CC       non-covalent binding of the propeptide to the catalytic domain.
CC       Inhibited by EGTA.
CC   -!- SUBUNIT: Monomer. Can self-associate to form dimers and higher
CC       multimers which may have increased LDLR degrading activity. The
CC       precursor protein but not the mature protein may form multimers.
CC       Interacts with APOB, VLDLR, LRP8/APOER2 and BACE1. The full-length
CC       immature form (pro-PCSK9) interacts with SCNN1A, SCNN1B and SCNN1G. The
CC       pro-PCSK9 form (via C-terminal domain) interacts with LDLR. Interacts
CC       (via the C-terminal domain) with ANXA2 (via repeat Annexin 1); the
CC       interaction inhibits the degradation of LDLR (PubMed:18799458).
CC       {ECO:0000269|PubMed:17461796, ECO:0000269|PubMed:18039658,
CC       ECO:0000269|PubMed:18197702, ECO:0000269|PubMed:18660751,
CC       ECO:0000269|PubMed:18799458, ECO:0000269|PubMed:21149300,
CC       ECO:0000269|PubMed:22493497, ECO:0000269|PubMed:22580899,
CC       ECO:0000269|PubMed:24808179}.
CC   -!- INTERACTION:
CC       Q8NBP7; P07355: ANXA2; NbExp=7; IntAct=EBI-7539251, EBI-352622;
CC       Q8NBP7; P01130: LDLR; NbExp=10; IntAct=EBI-7539251, EBI-988319;
CC       Q8NBP7; P08253: MMP2; NbExp=4; IntAct=EBI-7539251, EBI-1033518;
CC       Q8NBP7-1; P01130: LDLR; NbExp=4; IntAct=EBI-15656131, EBI-988319;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Secreted. Endosome. Lysosome. Cell
CC       surface. Endoplasmic reticulum. Golgi apparatus. Note=Autocatalytic
CC       cleavage is required to transport it from the endoplasmic reticulum to
CC       the Golgi apparatus and for the secretion of the mature protein.
CC       Localizes to the endoplasmic reticulum in the absence of LDLR and
CC       colocalizes to the cell surface and to the endosomes/lysosomes in the
CC       presence of LDLR. The sorting to the cell surface and endosomes is
CC       required in order to fully promote LDLR degradation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8NBP7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8NBP7-2; Sequence=VSP_008844, VSP_008845, VSP_008846;
CC   -!- TISSUE SPECIFICITY: Expressed in neuro-epithelioma, colon carcinoma,
CC       hepatic and pancreatic cell lines, and in Schwann cells.
CC   -!- DOMAIN: The C-terminal domain (CRD) is essential for the LDLR-binding
CC       and degrading activities. {ECO:0000269|PubMed:22027821}.
CC   -!- DOMAIN: The catalytic domain is responsible for mediating its self-
CC       association. {ECO:0000269|PubMed:22027821}.
CC   -!- PTM: Cleavage by furin and PCSK5 generates a truncated inactive protein
CC       that is unable to induce LDLR degradation.
CC       {ECO:0000269|PubMed:16912035}.
CC   -!- PTM: Undergoes autocatalytic cleavage in the endoplasmic reticulum to
CC       release the propeptide from the N-terminus and the cleavage of the
CC       propeptide is strictly required for its maturation and activation. The
CC       cleaved propeptide however remains associated with the catalytic domain
CC       through non-covalent interactions, preventing potential substrates from
CC       accessing its active site. As a result, it is secreted from cells as a
CC       propeptide-containing, enzymatically inactive protein.
CC       {ECO:0000269|PubMed:14622975}.
CC   -!- PTM: Phosphorylation protects the propeptide against proteolysis.
CC       {ECO:0000269|PubMed:18498363}.
CC   -!- POLYMORPHISM: Variant Leu-23 ins polymorphism in PCSK9 might have a
CC       modifier effect on LDLR mutation and familial hypercholesterolemia.
CC   -!- POLYMORPHISM: Genetic variations in PCSK9 define the low density
CC       lipoprotein cholesterol level quantitative trait locus 1 (LDLCQ1)
CC       [MIM:603776]. {ECO:0000269|PubMed:19319977,
CC       ECO:0000269|PubMed:22095935, ECO:0000269|PubMed:22417841}.
CC   -!- DISEASE: Hypercholesterolemia, familial, 3 (FHCL3) [MIM:603776]: A form
CC       of hypercholesterolemia, a disorder of lipoprotein metabolism
CC       characterized by elevated serum low-density lipoprotein (LDL)
CC       cholesterol levels, which result in excess deposition of cholesterol in
CC       tissues and leads to xanthelasma, xanthomas, accelerated
CC       atherosclerosis and increased risk of premature coronary heart disease.
CC       FHCL3 inheritance is autosomal dominant. {ECO:0000269|PubMed:12730697,
CC       ECO:0000269|PubMed:18799458, ECO:0000269|PubMed:19191301,
CC       ECO:0000269|PubMed:22095935, ECO:0000269|PubMed:24808179}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the peptidase S8 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC11572.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AX127530; CAC38896.1; -; mRNA.
DR   EMBL; EF692496; ABV59216.1; -; mRNA.
DR   EMBL; AK075365; BAC11572.1; ALT_FRAME; mRNA.
DR   EMBL; AK124635; BAC85910.1; -; mRNA.
DR   EMBL; AY829011; AAV67948.1; -; Genomic_DNA.
DR   EMBL; FJ525880; ACN81318.1; -; Genomic_DNA.
DR   EMBL; AC091609; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL589790; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471059; EAX06660.1; -; Genomic_DNA.
DR   CCDS; CCDS603.1; -. [Q8NBP7-1]
DR   RefSeq; NP_777596.2; NM_174936.3. [Q8NBP7-1]
DR   PDB; 2P4E; X-ray; 1.98 A; A/P=1-692.
DR   PDB; 2PMW; X-ray; 2.30 A; A=31-152, B=153-692.
DR   PDB; 2QTW; X-ray; 1.90 A; A=29-152, B=153-692.
DR   PDB; 2W2M; X-ray; 2.40 A; A=153-451, P=53-152.
DR   PDB; 2W2N; X-ray; 2.30 A; A=153-451, P=53-152.
DR   PDB; 2W2O; X-ray; 2.62 A; A=153-451, P=53-152.
DR   PDB; 2W2P; X-ray; 2.62 A; A=153-451, P=53-152.
DR   PDB; 2W2Q; X-ray; 2.33 A; A=153-451, P=53-152.
DR   PDB; 2XTJ; X-ray; 2.70 A; A=153-451, P=53-152.
DR   PDB; 3BPS; X-ray; 2.41 A; A=153-692, P=53-152.
DR   PDB; 3GCW; X-ray; 2.70 A; A=153-692, P=53-152.
DR   PDB; 3GCX; X-ray; 2.70 A; A=153-692, P=53-152.
DR   PDB; 3H42; X-ray; 2.30 A; A=31-152, B=153-692.
DR   PDB; 3M0C; X-ray; 7.01 A; A=29-152, B=153-692.
DR   PDB; 3P5B; X-ray; 3.30 A; A=153-692, P=61-152.
DR   PDB; 3P5C; X-ray; 4.20 A; A=153-692, P=61-152.
DR   PDB; 3SQO; X-ray; 2.70 A; A=153-692, P=31-152.
DR   PDB; 4K8R; X-ray; 3.22 A; A=61-152, B=153-692.
DR   PDB; 4NE9; X-ray; 2.60 A; A/B=153-692, C/P=1-152.
DR   PDB; 4NMX; X-ray; 1.85 A; A=31-152, B=153-452.
DR   PDB; 4OV6; X-ray; 2.69 A; A/D=60-152, B/E=153-446.
DR   PDB; 5OCA; X-ray; 2.30 A; A=31-152, B=153-692.
DR   PDB; 5VL7; X-ray; 3.50 A; A=31-152, B=153-692.
DR   PDB; 5VLA; X-ray; 2.40 A; A=1-452.
DR   PDB; 5VLH; X-ray; 2.86 A; A=1-452.
DR   PDB; 5VLK; X-ray; 2.20 A; A=1-452.
DR   PDB; 5VLL; X-ray; 2.37 A; A=1-452.
DR   PDB; 5VLP; X-ray; 2.90 A; A=1-692.
DR   PDB; 6E4Y; X-ray; 2.24 A; P=32-53.
DR   PDB; 6E4Z; X-ray; 2.20 A; P=32-53.
DR   PDB; 6MV5; X-ray; 2.10 A; P=32-53.
DR   PDB; 6OLZ; EM; 3.90 A; A=9-34.
DR   PDB; 6OM0; EM; 3.10 A; y=9-34.
DR   PDB; 6OM7; EM; 3.70 A; y=9-34.
DR   PDB; 6U26; X-ray; 1.53 A; A/B=31-692.
DR   PDB; 6U2F; X-ray; 2.94 A; A=1-692.
DR   PDB; 6U2N; X-ray; 2.15 A; A/B=31-692.
DR   PDB; 6U2P; X-ray; 2.04 A; A/B=31-692.
DR   PDB; 6U36; X-ray; 2.70 A; A/B=31-692.
DR   PDB; 6U38; X-ray; 2.73 A; A/B=31-692.
DR   PDB; 6U3I; X-ray; 2.90 A; A=1-692.
DR   PDB; 6U3X; X-ray; 2.64 A; A/B=31-692.
DR   PDB; 7ANQ; X-ray; 2.20 A; A=452-682.
DR   PDBsum; 2P4E; -.
DR   PDBsum; 2PMW; -.
DR   PDBsum; 2QTW; -.
DR   PDBsum; 2W2M; -.
DR   PDBsum; 2W2N; -.
DR   PDBsum; 2W2O; -.
DR   PDBsum; 2W2P; -.
DR   PDBsum; 2W2Q; -.
DR   PDBsum; 2XTJ; -.
DR   PDBsum; 3BPS; -.
DR   PDBsum; 3GCW; -.
DR   PDBsum; 3GCX; -.
DR   PDBsum; 3H42; -.
DR   PDBsum; 3M0C; -.
DR   PDBsum; 3P5B; -.
DR   PDBsum; 3P5C; -.
DR   PDBsum; 3SQO; -.
DR   PDBsum; 4K8R; -.
DR   PDBsum; 4NE9; -.
DR   PDBsum; 4NMX; -.
DR   PDBsum; 4OV6; -.
DR   PDBsum; 5OCA; -.
DR   PDBsum; 5VL7; -.
DR   PDBsum; 5VLA; -.
DR   PDBsum; 5VLH; -.
DR   PDBsum; 5VLK; -.
DR   PDBsum; 5VLL; -.
DR   PDBsum; 5VLP; -.
DR   PDBsum; 6E4Y; -.
DR   PDBsum; 6E4Z; -.
DR   PDBsum; 6MV5; -.
DR   PDBsum; 6OLZ; -.
DR   PDBsum; 6OM0; -.
DR   PDBsum; 6OM7; -.
DR   PDBsum; 6U26; -.
DR   PDBsum; 6U2F; -.
DR   PDBsum; 6U2N; -.
DR   PDBsum; 6U2P; -.
DR   PDBsum; 6U36; -.
DR   PDBsum; 6U38; -.
DR   PDBsum; 6U3I; -.
DR   PDBsum; 6U3X; -.
DR   PDBsum; 7ANQ; -.
DR   AlphaFoldDB; Q8NBP7; -.
DR   SMR; Q8NBP7; -.
DR   BioGRID; 129116; 138.
DR   ComplexPortal; CPX-128; LDLR-PCSK9 complex.
DR   ComplexPortal; CPX-130; ANXA2-PCSK9 complex.
DR   CORUM; Q8NBP7; -.
DR   DIP; DIP-29694N; -.
DR   FunCoup; Q8NBP7; 60.
DR   IntAct; Q8NBP7; 50.
DR   MINT; Q8NBP7; -.
DR   STRING; 9606.ENSP00000303208; -.
DR   BindingDB; Q8NBP7; -.
DR   ChEMBL; CHEMBL2929; -.
DR   DrugBank; DB09302; Alirocumab.
DR   DrugBank; DB09303; Evolocumab.
DR   DrugBank; DB14901; Inclisiran.
DR   DrugCentral; Q8NBP7; -.
DR   GuidetoPHARMACOLOGY; 2388; -.
DR   MEROPS; S08.039; -.
DR   GlyCosmos; Q8NBP7; 1 site, No reported glycans.
DR   GlyGen; Q8NBP7; 2 sites, 1 N-linked glycan (1 site).
DR   iPTMnet; Q8NBP7; -.
DR   PhosphoSitePlus; Q8NBP7; -.
DR   BioMuta; PCSK9; -.
DR   DMDM; 317373487; -.
DR   jPOST; Q8NBP7; -.
DR   MassIVE; Q8NBP7; -.
DR   PaxDb; 9606-ENSP00000303208; -.
DR   PeptideAtlas; Q8NBP7; -.
DR   ProteomicsDB; 72807; -. [Q8NBP7-1]
DR   ProteomicsDB; 72808; -. [Q8NBP7-2]
DR   Pumba; Q8NBP7; -.
DR   ABCD; Q8NBP7; 125 sequenced antibodies.
DR   Antibodypedia; 33231; 1115 antibodies from 45 providers.
DR   DNASU; 255738; -.
DR   Ensembl; ENST00000302118.5; ENSP00000303208.5; ENSG00000169174.13. [Q8NBP7-1]
DR   GeneID; 255738; -.
DR   KEGG; hsa:255738; -.
DR   MANE-Select; ENST00000302118.5; ENSP00000303208.5; NM_174936.4; NP_777596.2.
DR   UCSC; uc001cyf.3; human. [Q8NBP7-1]
DR   AGR; HGNC:20001; -.
DR   CTD; 255738; -.
DR   DisGeNET; 255738; -.
DR   GeneCards; PCSK9; -.
DR   GeneReviews; PCSK9; -.
DR   HGNC; HGNC:20001; PCSK9.
DR   HPA; ENSG00000169174; Tissue enriched (liver).
DR   MalaCards; PCSK9; -.
DR   MIM; 603776; phenotype.
DR   MIM; 607786; gene.
DR   OpenTargets; ENSG00000169174; -.
DR   Orphanet; 391665; Homozygous familial hypercholesterolemia.
DR   VEuPathDB; HostDB:ENSG00000169174; -.
DR   eggNOG; KOG1153; Eukaryota.
DR   GeneTree; ENSGT00490000043472; -.
DR   HOGENOM; CLU_011263_11_0_1; -.
DR   InParanoid; Q8NBP7; -.
DR   OMA; GEEMMGC; -.
DR   OrthoDB; 206201at2759; -.
DR   PAN-GO; Q8NBP7; 2 GO annotations based on evolutionary models.
DR   PhylomeDB; Q8NBP7; -.
DR   BRENDA; 3.4.21.61; 2681.
DR   PathwayCommons; Q8NBP7; -.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-8866427; VLDLR internalisation and degradation.
DR   Reactome; R-HSA-8957275; Post-translational protein phosphorylation.
DR   Reactome; R-HSA-8964038; LDL clearance.
DR   SignaLink; Q8NBP7; -.
DR   SIGNOR; Q8NBP7; -.
DR   BioGRID-ORCS; 255738; 37 hits in 1160 CRISPR screens.
DR   EvolutionaryTrace; Q8NBP7; -.
DR   GeneWiki; PCSK9; -.
DR   GenomeRNAi; 255738; -.
DR   Pharos; Q8NBP7; Tclin.
DR   PRO; PR:Q8NBP7; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q8NBP7; protein.
DR   Bgee; ENSG00000169174; Expressed in right lobe of liver and 114 other cell types or tissues.
DR   ExpressionAtlas; Q8NBP7; baseline and differential.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0030134; C:COPII-coated ER to Golgi transport vesicle; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0036020; C:endolysosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:HGNC-UCL.
DR   GO; GO:0031232; C:extrinsic component of external side of plasma membrane; IC:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005770; C:late endosome; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:1990667; C:PCSK9-AnxA2 complex; IDA:BHF-UCL.
DR   GO; GO:1990666; C:PCSK9-LDLR complex; IDA:BHF-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0034185; F:apolipoprotein binding; ISS:UniProtKB.
DR   GO; GO:0034190; F:apolipoprotein receptor binding; IDA:BHF-UCL.
DR   GO; GO:0030169; F:low-density lipoprotein particle binding; ISS:UniProtKB.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; IDA:HGNC-UCL.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IDA:HGNC-UCL.
DR   GO; GO:0030547; F:signaling receptor inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0019871; F:sodium channel inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0034189; F:very-low-density lipoprotein particle binding; ISS:UniProtKB.
DR   GO; GO:0070326; F:very-low-density lipoprotein particle receptor binding; IDA:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:HGNC-UCL.
DR   GO; GO:0009267; P:cellular response to starvation; ISS:HGNC-UCL.
DR   GO; GO:0042632; P:cholesterol homeostasis; IMP:HGNC-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0001822; P:kidney development; ISS:HGNC-UCL.
DR   GO; GO:0042157; P:lipoprotein metabolic process; IEA:Ensembl.
DR   GO; GO:0001889; P:liver development; ISS:HGNC-UCL.
DR   GO; GO:0032802; P:low-density lipoprotein particle receptor catabolic process; IDA:UniProtKB.
DR   GO; GO:0007041; P:lysosomal transport; IDA:BHF-UCL.
DR   GO; GO:0010989; P:negative regulation of low-density lipoprotein particle clearance; IDA:BHF-UCL.
DR   GO; GO:0002091; P:negative regulation of receptor internalization; IDA:ComplexPortal.
DR   GO; GO:0001920; P:negative regulation of receptor recycling; IDA:BHF-UCL.
DR   GO; GO:1905601; P:negative regulation of receptor-mediated endocytosis involved in cholesterol transport; IDA:BHF-UCL.
DR   GO; GO:1903783; P:negative regulation of sodium ion import across plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0022008; P:neurogenesis; ISS:HGNC-UCL.
DR   GO; GO:0030182; P:neuron differentiation; ISS:HGNC-UCL.
DR   GO; GO:0006644; P:phospholipid metabolic process; IEA:Ensembl.
DR   GO; GO:0032805; P:positive regulation of low-density lipoprotein particle receptor catabolic process; IDA:BHF-UCL.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IMP:HGNC-UCL.
DR   GO; GO:0002092; P:positive regulation of receptor internalization; IDA:BHF-UCL.
DR   GO; GO:0016540; P:protein autoprocessing; IDA:HGNC-UCL.
DR   GO; GO:0043523; P:regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0006641; P:triglyceride metabolic process; IEA:Ensembl.
DR   CDD; cd16839; PCSK9_C-CRD; 1.
DR   CDD; cd04077; Peptidases_S8_PCSK9_ProteinaseK_like; 1.
DR   DisProt; DP02551; -.
DR   FunFam; 2.60.120.690:FF:000001; Proprotein convertase subtilisin/kexin type 9; 1.
DR   FunFam; 3.30.70.80:FF:000004; Proprotein convertase subtilisin/kexin type 9; 1.
DR   FunFam; 3.40.50.200:FF:000016; Proprotein convertase subtilisin/kexin type 9; 1.
DR   Gene3D; 3.30.70.80; Peptidase S8 propeptide/proteinase inhibitor I9; 1.
DR   Gene3D; 3.40.50.200; Peptidase S8/S53 domain; 1.
DR   Gene3D; 2.60.120.690; Proprotein convertase subtilisin/kexin type 9; 1.
DR   InterPro; IPR041254; PCSK9_C1.
DR   InterPro; IPR041052; PCSK9_C2.
DR   InterPro; IPR041051; PCSK9_C3.
DR   InterPro; IPR034193; PCSK9_ProteinaseK-like.
DR   InterPro; IPR000209; Peptidase_S8/S53_dom.
DR   InterPro; IPR036852; Peptidase_S8/S53_dom_sf.
DR   InterPro; IPR050131; Peptidase_S8_subtilisin-like.
DR   InterPro; IPR015500; Peptidase_S8_subtilisin-rel.
DR   InterPro; IPR010259; S8pro/Inhibitor_I9.
DR   InterPro; IPR037045; S8pro/Inhibitor_I9_sf.
DR   PANTHER; PTHR43806; PEPTIDASE S8; 1.
DR   PANTHER; PTHR43806:SF60; PROPROTEIN CONVERTASE SUBTILISIN_KEXIN TYPE 9; 1.
DR   Pfam; PF05922; Inhibitor_I9; 1.
DR   Pfam; PF18459; PCSK9_C1; 1.
DR   Pfam; PF18464; PCSK9_C2; 1.
DR   Pfam; PF18463; PCSK9_C3; 1.
DR   Pfam; PF00082; Peptidase_S8; 1.
DR   PRINTS; PR00723; SUBTILISIN.
DR   SUPFAM; SSF54897; Protease propeptides/inhibitors; 1.
DR   SUPFAM; SSF52743; Subtilisin-like; 1.
DR   PROSITE; PS51892; SUBTILASE; 1.
DR   neXtProt; NX_Q8NBP7; -.
DR   PharmGKB; PA38617; -.
DR   TreeFam; TF106271; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Autocatalytic cleavage;
KW   Calcium; Cholesterol metabolism; Cytoplasm; Direct protein sequencing;
KW   Disease variant; Disulfide bond; Endoplasmic reticulum; Endosome;
KW   Glycoprotein; Golgi apparatus; Hydrolase; Lipid metabolism; Lysosome;
KW   Phosphoprotein; Protease; Proteomics identification; Reference proteome;
KW   Secreted; Serine protease; Signal; Steroid metabolism; Sterol metabolism;
KW   Sulfation; Zymogen.
FT   SIGNAL          1..30
FT                   /evidence="ECO:0000269|PubMed:12552133"
FT   PROPEP          31..152
FT                   /evidence="ECO:0000269|PubMed:12552133"
FT                   /id="PRO_0000027120"
FT   CHAIN           153..692
FT                   /note="Proprotein convertase subtilisin/kexin type 9"
FT                   /id="PRO_0000027121"
FT   DOMAIN          77..149
FT                   /note="Inhibitor I9"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          155..461
FT                   /note="Peptidase S8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01240"
FT   REGION          450..692
FT                   /note="C-terminal domain"
FT   ACT_SITE        186
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01240"
FT   ACT_SITE        226
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01240"
FT   ACT_SITE        386
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01240"
FT   SITE            152..153
FT                   /note="Cleavage; by autolysis"
FT                   /evidence="ECO:0000269|PubMed:14622975"
FT   SITE            218..219
FT                   /note="Cleavage; by furin and PCSK5"
FT                   /evidence="ECO:0000269|PubMed:16912035"
FT   MOD_RES         38
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000269|PubMed:16912035"
FT   MOD_RES         47
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:18498363,
FT                   ECO:0000269|PubMed:26091039"
FT   MOD_RES         688
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:18498363,
FT                   ECO:0000269|PubMed:26091039, ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   CARBOHYD        533
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16912035"
FT   DISULFID        223..255
FT                   /evidence="ECO:0000255"
FT   DISULFID        323..358
FT                   /evidence="ECO:0000255"
FT   DISULFID        457..527
FT                   /evidence="ECO:0000255"
FT   DISULFID        477..526
FT                   /evidence="ECO:0000255"
FT   DISULFID        486..509
FT                   /evidence="ECO:0000255"
FT   DISULFID        534..601
FT                   /evidence="ECO:0000255"
FT   DISULFID        552..600
FT                   /evidence="ECO:0000255"
FT   DISULFID        562..588
FT                   /evidence="ECO:0000255"
FT   DISULFID        608..679
FT                   /evidence="ECO:0000255"
FT   DISULFID        626..678
FT                   /evidence="ECO:0000255"
FT   DISULFID        635..654
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1..174
FT                   /note="MGTVSSRRSWWPLPLLLLLLLLLGPAGARAQEDEDGDYEELVLALRSEEDGL
FT                   AEAPEHGTTATFHRCAKDPWRLPGTYVVVLKEETHLSQSERTARRLQAQAARRGYLTKI
FT                   LHVFHGLLPGFLVKMSGDLLELALKLPHVDYIEEDSSVFAQSIPWNLERITPPRYRADE
FT                   YQPP -> MSPWK (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_008844"
FT   VAR_SEQ         333..365
FT                   /note="VITVGATNAQDQPVTLGTLGTNFGRCVDLFAPG -> GRTSLVPPATAAPAL
FT                   CHRVGHHRLLPTWLALQP (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_008845"
FT   VAR_SEQ         366..692
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_008846"
FT   VARIANT         23
FT                   /note="L -> LL (this variant seems to have a modifier
FT                   effect on LDLR mutation and familial hypercholesterolemia)"
FT                   /evidence="ECO:0000269|PubMed:19319977,
FT                   ECO:0000269|PubMed:22095935, ECO:0000269|Ref.4,
FT                   ECO:0000269|Ref.5"
FT                   /id="VAR_021336"
FT   VARIANT         46
FT                   /note="R -> L (correlated with lower plasma levels of
FT                   low-density lipoprotein cholesterol; reduced
FT                   phosphorylation at Ser-47; dbSNP:rs11591147)"
FT                   /evidence="ECO:0000269|PubMed:12730697,
FT                   ECO:0000269|PubMed:16465619, ECO:0000269|PubMed:22095935,
FT                   ECO:0000269|Ref.4"
FT                   /id="VAR_017197"
FT   VARIANT         53
FT                   /note="A -> V (reduced phosphorylation at Ser-47;
FT                   dbSNP:rs11583680)"
FT                   /evidence="ECO:0000269|PubMed:12730697,
FT                   ECO:0000269|PubMed:16465619, ECO:0000269|PubMed:22095935,
FT                   ECO:0000269|Ref.4"
FT                   /id="VAR_017198"
FT   VARIANT         57
FT                   /note="E -> K (in dbSNP:rs145886902)"
FT                   /evidence="ECO:0000269|PubMed:16465619"
FT                   /id="VAR_025451"
FT   VARIANT         77
FT                   /note="T -> I (in dbSNP:rs756060557)"
FT                   /id="VAR_058520"
FT   VARIANT         93
FT                   /note="R -> C (in dbSNP:rs151193009)"
FT                   /id="VAR_058521"
FT   VARIANT         106
FT                   /note="G -> R (in dbSNP:rs2100267180)"
FT                   /id="VAR_058522"
FT   VARIANT         114
FT                   /note="V -> A (in dbSNP:rs775988212)"
FT                   /id="VAR_058523"
FT   VARIANT         127
FT                   /note="S -> R (in FHCL3; dbSNP:rs28942111)"
FT                   /evidence="ECO:0000269|PubMed:12730697"
FT                   /id="VAR_017199"
FT   VARIANT         129
FT                   /note="D -> G (in FHCL3; dbSNP:rs1553135971)"
FT                   /evidence="ECO:0000269|PubMed:19191301"
FT                   /id="VAR_058524"
FT   VARIANT         157
FT                   /note="N -> K (in dbSNP:rs143117125)"
FT                   /id="VAR_058525"
FT   VARIANT         174
FT                   /note="P -> S (found in patients with familial
FT                   hypercholesterolemia carrying a homozygous LDLR mutation;
FT                   acts as a disease modifier resulting in a mild phenotype;
FT                   dbSNP:rs533273863)"
FT                   /evidence="ECO:0000269|PubMed:22417841"
FT                   /id="VAR_067351"
FT   VARIANT         215
FT                   /note="R -> H (in FHCL3; dbSNP:rs794728683)"
FT                   /evidence="ECO:0000269|PubMed:19191301"
FT                   /id="VAR_058526"
FT   VARIANT         216
FT                   /note="F -> L (in FHCL3; partial loss of cleavage by furin
FT                   and PCSK5; dbSNP:rs28942112)"
FT                   /evidence="ECO:0000269|PubMed:12730697"
FT                   /id="VAR_017200"
FT   VARIANT         218
FT                   /note="R -> S (in FHCL3; complete loss of cleavage by furin
FT                   and PCSK5; reduces glycosylation levels; no effect on
FT                   protein sulfation and phosphorylation; no effect on protein
FT                   sulfation but inhibits phosphorylation when associated with
FT                   Y-374; highly reduces LDL uptake when associated with
FT                   Y-374; dbSNP:rs970575319)"
FT                   /evidence="ECO:0000269|PubMed:18799458,
FT                   ECO:0000269|PubMed:24808179"
FT                   /id="VAR_058527"
FT   VARIANT         219
FT                   /note="Q -> E (in dbSNP:rs778617372)"
FT                   /id="VAR_058528"
FT   VARIANT         237
FT                   /note="R -> W (in dbSNP:rs148195424)"
FT                   /evidence="ECO:0000269|PubMed:16465619"
FT                   /id="VAR_025452"
FT   VARIANT         239
FT                   /note="A -> D"
FT                   /id="VAR_058529"
FT   VARIANT         253
FT                   /note="L -> F (correlated with lower plasma levels of
FT                   low-density lipoprotein cholesterol; dbSNP:rs72646508)"
FT                   /evidence="ECO:0000269|PubMed:16465619"
FT                   /id="VAR_025453"
FT   VARIANT         357
FT                   /note="R -> H (in FHCL3; dbSNP:rs370507566)"
FT                   /evidence="ECO:0000269|PubMed:19191301"
FT                   /id="VAR_058530"
FT   VARIANT         374
FT                   /note="D -> H (in FHCL3; dbSNP:rs137852912)"
FT                   /evidence="ECO:0000269|PubMed:19191301"
FT                   /id="VAR_058531"
FT   VARIANT         374
FT                   /note="D -> Y (in FHCL3; partial loss of cleavage by furin
FT                   and PCSK5; no effect on protein sulfation but inhibits
FT                   phosphorylation when associated with S-218; highly
FT                   increases LDL uptake when associated with S-218;
FT                   dbSNP:rs137852912)"
FT                   /evidence="ECO:0000269|PubMed:18799458,
FT                   ECO:0000269|PubMed:24808179"
FT                   /id="VAR_058532"
FT   VARIANT         391
FT                   /note="H -> N (in dbSNP:rs146471967)"
FT                   /evidence="ECO:0000269|PubMed:16465619"
FT                   /id="VAR_025454"
FT   VARIANT         394
FT                   /note="G -> S (in FHCL3; uncertain significance;
FT                   dbSNP:rs368257906)"
FT                   /evidence="ECO:0000269|PubMed:22095935"
FT                   /id="VAR_067282"
FT   VARIANT         417
FT                   /note="H -> Q (in dbSNP:rs143275858)"
FT                   /evidence="ECO:0000269|PubMed:16465619"
FT                   /id="VAR_025455"
FT   VARIANT         425
FT                   /note="N -> S (in dbSNP:rs28362261)"
FT                   /evidence="ECO:0000269|PubMed:16465619, ECO:0000269|Ref.4"
FT                   /id="VAR_021337"
FT   VARIANT         443
FT                   /note="A -> T (correlated with lower plasma levels of
FT                   low-density lipoprotein cholesterol; more extensive
FT                   cleavage by furin and PCSK5; dbSNP:rs28362263)"
FT                   /evidence="ECO:0000269|PubMed:16465619, ECO:0000269|Ref.4"
FT                   /id="VAR_021338"
FT   VARIANT         452
FT                   /note="G -> D (in dbSNP:rs1210806532)"
FT                   /id="VAR_058533"
FT   VARIANT         469
FT                   /note="R -> W (in dbSNP:rs141502002)"
FT                   /evidence="ECO:0000269|PubMed:16465619"
FT                   /id="VAR_025456"
FT   VARIANT         474
FT                   /note="V -> I (in dbSNP:rs562556)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:16465619, ECO:0000269|PubMed:17971861,
FT                   ECO:0000269|PubMed:22095935, ECO:0000269|Ref.1,
FT                   ECO:0000269|Ref.4, ECO:0000269|Ref.5, ECO:0000269|Ref.7"
FT                   /id="VAR_021339"
FT   VARIANT         482
FT                   /note="E -> G (in dbSNP:rs141995194)"
FT                   /evidence="ECO:0000269|PubMed:16465619"
FT                   /id="VAR_025457"
FT   VARIANT         482
FT                   /note="E -> Q (no effect on interaction with ANXA2)"
FT                   /evidence="ECO:0000269|PubMed:24808179"
FT                   /id="VAR_073657"
FT   VARIANT         496
FT                   /note="R -> W (in FHCL3; dbSNP:rs374603772)"
FT                   /evidence="ECO:0000269|PubMed:19191301"
FT                   /id="VAR_058534"
FT   VARIANT         515
FT                   /note="F -> L (in dbSNP:rs1356131564)"
FT                   /evidence="ECO:0000269|PubMed:16465619"
FT                   /id="VAR_025458"
FT   VARIANT         522
FT                   /note="A -> T (in dbSNP:rs777300852)"
FT                   /id="VAR_058535"
FT   VARIANT         553
FT                   /note="H -> R (in dbSNP:rs28362270)"
FT                   /evidence="ECO:0000269|PubMed:16465619, ECO:0000269|Ref.4"
FT                   /id="VAR_021340"
FT   VARIANT         554
FT                   /note="Q -> E (increases interaction with ANXA2;
FT                   dbSNP:rs149311926)"
FT                   /evidence="ECO:0000269|PubMed:16465619,
FT                   ECO:0000269|PubMed:18799458"
FT                   /id="VAR_025459"
FT   VARIANT         616
FT                   /note="P -> L (in dbSNP:rs755750316)"
FT                   /id="VAR_058536"
FT   VARIANT         619
FT                   /note="Q -> P (in dbSNP:rs28362277)"
FT                   /evidence="ECO:0000269|PubMed:16465619, ECO:0000269|Ref.4"
FT                   /id="VAR_021341"
FT   VARIANT         668
FT                   /note="S -> R (in dbSNP:rs762298323)"
FT                   /id="VAR_058537"
FT   VARIANT         670
FT                   /note="G -> E (in dbSNP:rs505151)"
FT                   /evidence="ECO:0000269|PubMed:12730697,
FT                   ECO:0000269|PubMed:16465619, ECO:0000269|PubMed:17971861,
FT                   ECO:0000269|PubMed:22095935, ECO:0000269|Ref.1,
FT                   ECO:0000269|Ref.4, ECO:0000269|Ref.5, ECO:0000269|Ref.7"
FT                   /id="VAR_017201"
FT   MUTAGEN         67
FT                   /note="C->A: Does not affect multimerization or zymogen
FT                   processing."
FT                   /evidence="ECO:0000269|PubMed:12552133"
FT   MUTAGEN         226
FT                   /note="H->A: Remains in the endoplasmic reticulum and is
FT                   not secreted."
FT                   /evidence="ECO:0000269|PubMed:12552133"
FT   MUTAGEN         533
FT                   /note="N->A: 1.5 kDa decrease of the apparent molecular
FT                   mass of pro-PCSK9 and PCSK9 and no effect on processing and
FT                   secretion."
FT                   /evidence="ECO:0000269|PubMed:12552133"
FT   CONFLICT        423
FT                   /note="V -> A (in Ref. 3; BAC11572)"
FT                   /evidence="ECO:0000305"
FT   STRAND          34..36
FT                   /evidence="ECO:0007829|PDB:6MV5"
FT   HELIX           37..45
FT                   /evidence="ECO:0007829|PDB:6MV5"
FT   STRAND          63..65
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   HELIX           70..72
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          73..82
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          84..86
FT                   /evidence="ECO:0007829|PDB:4OV6"
FT   HELIX           88..104
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          110..115
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          117..119
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          121..125
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   HELIX           128..130
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   HELIX           131..135
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          140..151
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   HELIX           156..160
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   HELIX           168..170
FT                   /evidence="ECO:0007829|PDB:3BPS"
FT   STRAND          180..187
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   TURN            194..199
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          200..206
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          212..214
FT                   /evidence="ECO:0007829|PDB:4NMX"
FT   TURN            218..220
FT                   /evidence="ECO:0007829|PDB:3H42"
FT   TURN            221..224
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   HELIX           225..235
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   TURN            237..239
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          241..244
FT                   /evidence="ECO:0007829|PDB:2P4E"
FT   STRAND          246..251
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          257..260
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   HELIX           261..277
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          283..287
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          289..292
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   HELIX           295..306
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          310..314
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          317..321
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   HELIX           322..324
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   TURN            327..329
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          333..339
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          343..345
FT                   /evidence="ECO:0007829|PDB:2PMW"
FT   STRAND          349..352
FT                   /evidence="ECO:0007829|PDB:2W2Q"
FT   STRAND          355..358
FT                   /evidence="ECO:0007829|PDB:3P5B"
FT   STRAND          361..364
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          366..371
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          373..375
FT                   /evidence="ECO:0007829|PDB:5VLL"
FT   STRAND          379..382
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   HELIX           385..402
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   HELIX           408..418
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          419..422
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   HELIX           426..428
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   HELIX           431..433
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   TURN            434..436
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          440..442
FT                   /evidence="ECO:0007829|PDB:3P5B"
FT   STRAND          457..461
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          469..471
FT                   /evidence="ECO:0007829|PDB:6U3X"
FT   STRAND          472..475
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          482..489
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          491..493
FT                   /evidence="ECO:0007829|PDB:3GCX"
FT   STRAND          495..501
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          508..513
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          515..517
FT                   /evidence="ECO:0007829|PDB:5OCA"
FT   STRAND          521..527
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          535..539
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          544..546
FT                   /evidence="ECO:0007829|PDB:2QTW"
FT   STRAND          549..551
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          554..556
FT                   /evidence="ECO:0007829|PDB:5VL7"
FT   STRAND          557..565
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          568..570
FT                   /evidence="ECO:0007829|PDB:2P4E"
FT   STRAND          587..589
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          594..602
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          606..615
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          621..625
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          631..637
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   TURN            641..643
FT                   /evidence="ECO:0007829|PDB:6U3I"
FT   STRAND          644..650
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          653..658
FT                   /evidence="ECO:0007829|PDB:6U26"
FT   STRAND          672..681
FT                   /evidence="ECO:0007829|PDB:6U26"
SQ   SEQUENCE   692 AA;  74286 MW;  9BCB9418B90AEE23 CRC64;
     MGTVSSRRSW WPLPLLLLLL LLLGPAGARA QEDEDGDYEE LVLALRSEED GLAEAPEHGT
     TATFHRCAKD PWRLPGTYVV VLKEETHLSQ SERTARRLQA QAARRGYLTK ILHVFHGLLP
     GFLVKMSGDL LELALKLPHV DYIEEDSSVF AQSIPWNLER ITPPRYRADE YQPPDGGSLV
     EVYLLDTSIQ SDHREIEGRV MVTDFENVPE EDGTRFHRQA SKCDSHGTHL AGVVSGRDAG
     VAKGASMRSL RVLNCQGKGT VSGTLIGLEF IRKSQLVQPV GPLVVLLPLA GGYSRVLNAA
     CQRLARAGVV LVTAAGNFRD DACLYSPASA PEVITVGATN AQDQPVTLGT LGTNFGRCVD
     LFAPGEDIIG ASSDCSTCFV SQSGTSQAAA HVAGIAAMML SAEPELTLAE LRQRLIHFSA
     KDVINEAWFP EDQRVLTPNL VAALPPSTHG AGWQLFCRTV WSAHSGPTRM ATAVARCAPD
     EELLSCSSFS RSGKRRGERM EAQGGKLVCR AHNAFGGEGV YAIARCCLLP QANCSVHTAP
     PAEASMGTRV HCHQQGHVLT GCSSHWEVED LGTHKPPVLR PRGQPNQCVG HREASIHASC
     CHAPGLECKV KEHGIPAPQE QVTVACEEGW TLTGCSALPG TSHVLGAYAV DNTCVVRSRD
     VSTTGSTSEG AVTAVAICCR SRHLAQASQE LQ
//
